Table 1.

Baseline characteristics of the Chronic Renal Insufficiency Cohort Study participants on the basis of whether they ever reported nonsteroidal anti-inflammatory drug use at a study visit (n=3872)

Baseline CharacteristicsTotalNSAID UseP Value
Ever (Column %)Never (Column %)
All38729402932
Age, yr0.004
 <45513123 (13)390 (13)
 45–<652227581 (62)1646 (56)
 ≥651132236 (25)896 (31)
Race0.11
 Nonblack2241565 (60)1676 (57)
 Black1631375 (40)1256 (42.8)
Sex<0.001
 Men2125430 (46)1695 (58)
 Women1747510 (54)1237 (42)
CKD stage at baseline<0.001
 1/2389186 (20)203 (7)
 3A1242386 (41)856 (29)
 3B1486301 (32)1185 (40)
 4/575567 (7)688 (24)
Urine protein, g/24 h<0.001
 <0.11350476 (53)874 (31)
 0.1 to <0.51076246 (27)830 (30)
 ≥0.51253183 (20)1070 (39)
BMI0.01
 <25.0614121 (13)493 (17)
 25.0 to <30.01099264 (28)835 (28)
 ≥30.02149552 (59)1597 (55)
Diabetes<0.001
 No1979568 (60)1411 (48)
 Yes1893372 (40)1521 (52)
CVD<0.001
 No2567680 (72)1887 (64)
 Yes1305260 (28)1045 (36)
Hypertension<0.001
 No511165 (186)346 (12)
 Yes3361775 (82)2586 (88)
Arthritis0.04
 No3190759 (85)2431 (87)
 Yes489137 (15)352 (13)
Nephrologist visit<0.001
 No1310483 (51)827 (28)
 Yes2562457 (49)2105 (72)
Pain interfering moderately or greater with work<0.001
 No2490543 (58)1947 (67)
 Yes1362394 (42)968 (33)
SF12-PCS (mean±SD)41.2±11.541.2±11.641.2±11.50.86
  • All variables were measured at baseline, except for never/ever NSAID use, which is a cumulative variable including any NSAID use at baseline or follow-up visits. NSAID, nonsteroidal anti-inflammatory drug; BMI, body mass index; CVD, cardiovascular disease; SF12-PCS, SF12 Physical Health Composite Score.